Immuron Ltd — Investor Presentation 2015

Oct 21, 2015

==> picture [221 x 62] intentionally omitted <==

Immuron to Present at the RedChip Global Online Microcap Conference

22[nd] October, 2015 – Melbourne, Australia: Mr Thomas Liquard, CEO of Immuron Limited (ASX: IMC; OTC US: IMROY), is scheduled to present at the RedChip Global Online Microcap Conference on Thursday 22[nd] October, 2015, at 9:30AM US Eastern time. The presentation can be viewed at www.RedChip.com.

A live Q&A session will follow the investor presentation. Investors can pre-submit their questions by visiting http://www.redchip.com/events/3/global-online-microcap-conference.

The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip’s microcap conference series each year.

No registration is required to participate in the conference. Start times are subject to change.

As previously announced, Immuron engaged Red Chip for the provision of certain US Investor Relations Services. On 20[th] August 2015 Red Chip released an Analyst Report which attracted significant online and market attention. A copy of this report is available at www.immuron.com/index.php/download_file//view/140/.

Contact:

Thomas Liquard Jon Cunningham Chief Executive Officer RedChip Companies, Inc. AUS Ph: +61 (0)3 9824 5254 US Tel: 0011 1-800-RED-CHIP (733-2447), ext. 107 Email: thomasliquard@immuron.com Email: info@redchip.com

About RedChip Companies, Inc.

RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, “The RedChip Money Report: Small Stocks Big Money”™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. www.redchip.com

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

COMPANY PRESENTATION
----- End of picture text -----

October 2015

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Forward-Looking Statement
Certain statements made in this presentation are forward-looking statements and are based on
Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to
identify forward-looking statements.
Although Immuron believes the forward-looking statements are based on reasonable assumptions,
they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control,
including those risks or uncertainties inherent in the process of both developing and commercializing
----- End of picture text -----

2

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Corporate Overview
•
Unique and Leverageable Platform – Proprietary oral immunotherapy
technology targeting microbiome and inflammation with broad utility
•
Attracting Leading Collaborations – NIH, Renowned experts and institutions
•
Strong Pipeline – High value indications, with leading competitive profiles
•
Phase II in NASH (Fatty-Liver Disease)
----- End of picture text -----

3

NASH and Two Phase II studies in progress with ASH: an increasingly alluring potential upside

Travelan:

Pipeline:

Revenues growing and positioned to grow further with successful USA launch Progressing; potential for multi-billion $ assets

Cap Profile: Robust

Financials:

Debt free, cash in the bank until after completion of NASH trial

4

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

… With Significant Room for Valuation Upside
NASH Peer Comparables
----- End of picture text -----

5

6

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Strong Financial Position:
•
Ticker Code: IMC.AX (Australia)
• Share price: (as at 22 October 2015) AUD$0.51; USD$0.37
----- End of picture text -----

PIPELINE

• IMM-124E (anti LPS + adjuvants) for NASH

8

NASH – Pathogenesis

IMM-124E – MOA

Unique Properties

1 2

Decrease systemic and local inflammation

Decreases liver inflammation - Improves liver function9

==> picture [262 x 59] intentionally omitted <==

----- Start of picture text -----

Fibrotic Liver
----- End of picture text -----

IMM-124E Treated Liver

==> picture [262 x 278] intentionally omitted <==

==> picture [101 x 172] intentionally omitted <==

----- Start of picture text -----

IMM-
124E
----- End of picture text -----

==> picture [262 x 278] intentionally omitted <==

Mizrahi M. 2013, AASLD; Hepatology 751A

10

Group A: Group B: Control Naïve anti LPS Group C: Group D: Treated Treated

Group A: Group B: Naïve Control anti LPS

==> picture [698 x 307] intentionally omitted <==

----- Start of picture text -----

Group C: Group D: Group C: Group D:
Treated Treated Treated Treated
Decreased Portal Inflammation
Improved Metavir Fibrosis Score
3 4
3.4
2.4 3.5
2.5
3
2
2.5
1.4 1.33
1.8
1.5 2
1 0.66 1.5 1
1
0.5 p<0.0009
p<0.02 0.5
0 ^^ p<0.0003
0 ^^ p<0.01 0
A B C D A B C D
11
Mizrahi M. 2013, AASLD; Hepatology 751A
----- End of picture text -----

Improved Liver Enzymes

==> picture [343 x 171] intentionally omitted <==

Improved HBA1C, OGTT and HOMA

==> picture [344 x 249] intentionally omitted <==

Mizrahi M, J Inflamm Res. 2012;5:141-50

12

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

NASH – A $35B - $40B Market
Major Commercial Opportunity
•
25% of the US population has NAFLD
•
5% of the population will develop NASH
•
No treatments approved
----- End of picture text -----

Estimated Market Size: $35B - $40B USD by 2025 (Deutsche Bank)

13

• IMM-529 for Clostridium Difficile

14

Center for Disease Control (CDC) Antibiotic Resistance Threats in the United States, 2013

==> picture [649 x 126] intentionally omitted <==

15

• Prophylaxis – Demonstrating effectiveness in 80% of cases

• Treatment – Prevented death in 80% of cases

Prophylaxis

Treatment

16

TRAVELAN[®] Stop it before it starts

• Marketed in the US, Australia by Immuron and by Paladin/Endo in Canada

• Global market estimate: US$ 600M - 1.2B

• All-natural product;

• Clinically proven

• SAFE

• OTC

• Strong brand loyalty

• Multiple life-cycle opportunities

18

Country Discussions Term Sheet Licensed Regulatory In Market Canada South Korea Other Asian Countries United States

India China

• Regulatory application preceding partnering engagement

19

SUMMARY

==> picture [721 x 271] intentionally omitted <==

NASH and Two Phase II studies in progress with ASH: an increasingly alluring potential upside Travelan:

Revenues growing and positioned to grow further with successful USA launch Progressing; potential for multi-billion $ assets

Pipeline:

Cap Profile: Robust

Financials:

Debt free, cash in the bank until after completion of NASH trial

21

The Board and Management

Chairman

Non-executive Director

Non-executive Director

Chief Executive Officer

Head of Medical

COO & Scientific Officer

Clinical Director

Manufacturing Quality Director

Medical and Scientific Advisor

22

THANK YOU

==> picture [721 x 271] intentionally omitted <==